Overview

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Conatumumab
Panitumumab